Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 24;60(Suppl 6):vi53-vi61.
doi: 10.1093/rheumatology/keab466.

New developments in Sjogren's syndrome

Nishanthi Thalayasingam  1 , Kelly Baldwin  1 , Claire Judd  1 , Wan-Fai Ng  1   2
Affiliations
Review

New developments in Sjogren's syndrome

Nishanthi Thalayasingam et al. Rheumatology (Oxford). .

Abstract

SS is a chronic, autoimmune condition characterized by lymphocytic infiltration of the exocrine glands and B-cell dysfunction. Current treatment strategies are largely empirical and offer only symptomatic relief for patients. There are no proven treatments that alter disease progression or treat the systemic manifestations of disease. B-cell depletion is used in patients with systemic disease but its overall clinical efficacy has not been demonstrated in two large randomized controlled trials. Studies are now focussing on alternative strategies to target B-cells, including co-stimulation targets, with promising data. It is increasingly clear that clinical trials in SS will require patient stratification and relevant and sensitive outcome measures to identify successful treatment modalities.

Keywords: B-cells; BAFF; CD40; SS; biologics; outcome measures; stratification.

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Lymphocytic infiltration of the salivary gland in SS and potential therapeutic targets T-cell help is required to form ectopic lymphoid structures (ELS) in the salivary gland. Strategies to treat SS include: a direct effect on B-cells, B-cell activating factor (BAFF), its receptor (BAFF-R) or co-stimulation molecules. BAFF: B-cell activating factor, BAFF-R: B-cell activating factor receptor. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Mariette X, Criswell LA.. Primary Sjogren's Syndrome. N Engl J Med 2018;378:931–9. - PubMed
    1. Theander E, Henriksson G, Ljungberg O. et al. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796–803. - PMC - PubMed
    1. Meijer JM, Meiners PM, Huddleston Slater JJ. et al. Health-related quality of life, employment and disability in patients with Sjogren's syndrome. Rheumatology 2009;48:1077–82. - PubMed
    1. Price EJ, Rauz S, Tappuni AR. et al. The British Society for Rheumatology guideline for the management of adults with primary Sjogren's Syndrome. Rheumatology 2017;56:1828. - PubMed
    1. Groom J, Kalled SL, Cutler AH. et al. Association of BAFF/BLyS overexpression and altered B-cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109:59–68. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources